Who is sponsoring NCT00124007?

NCT00124007 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

What condition does NCT00124007 study?

NCT00124007 studies HIV Infections.

What drugs are being tested in NCT00124007?

Interventions: VRC-HIVADV014-00-VP, VRC-HIVDNA016-00-VP.

What is the status of NCT00124007?

NCT00124007 is currently COMPLETED.

Last reviewed 2021-10-28 · How we verify

A Phase I, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by Recombinant, Multiclade HIV-1 Adenoviral Vector Vaccine or the Multiclade HIV-1 Adenoviral Vector Vaccine Alone in Healthy Adult Volunteers Not Infected With HIV

NCT00124007 Phase 1 COMPLETED

The purpose of this study is to determine the safety of and immune response to an investigational HIV vaccine, VRC-HIVADV014-00-VP, with or without a second investigational HIV vaccine, VRC-HIVDNA016-00-VP, in HIV uninfected adults.

Details

Lead sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Phase	Phase 1
Status	COMPLETED
Enrolment	114
Start date	2005-11
Completion	2007-04

Conditions

HIV Infections

Interventions

VRC-HIVADV014-00-VP
VRC-HIVDNA016-00-VP

Primary outcomes

Local reactogenicity signs and symptoms
systemic reactogenicity signs and symptoms
laboratory measures of safety
adverse and serious adverse experiences

Countries

Kenya, Rwanda